基于电子鼻技术的Ⅰ期肺癌真实世界评估
这项Ⅱc期试验(NCT04734145)纳入100例单发≥50%实性Ⅰ期结节患者,前瞻性收集2020年1月至2023年8月呼气样本,由盲法生物工程师用电子鼻技术判定恶性概率。以预设 cutoff<0.20 判定,电子鼻与组织病理结果一致率为86%,F1评分92.5%;电子鼻较Swensen和Brock模型将更少恶性结节患者转至观察、更多转至无活检治疗。
要点
- Ⅰ期肺癌中电子鼻与组织病理一致率86%,F1评分92.5%(n=100)。
- 电子鼻将恶性结节转观察者少于Swensen和Brock模型(低风险2 vs 9和11)。
- 电子鼻将恶性结节转无活检治疗者多于两模型(高风险27 vs 19和6)。
核心结论
- 在临床Ⅰ期肺癌中,电子鼻与组织病理结果吻合良好,可作为影像学的补充或作为「多组学」平台的一部分使用。
研究设计与样本
- Ⅱc期试验(NCT04734145),纳入诊断为单发≥50%实性Ⅰ期结节的患者,前瞻性收集2020年1月至2023年8月的呼气样本,由盲法生物工程师用电子鼻技术判定恶性概率,并与组织病理及临床影像预测模型比较。
主要发现
- 基于预设 cutoff<0.20,电子鼻与组织病理结果在86%的病例中一致,F1评分为92.5%,基于86例真阳性、2例假阴性和12例假阳性(n=100)。
- 电子鼻将恶性结节患者转至观察的人数少于Swensen和Brock模型(低风险组:2 vs 9和11,p=0.028和p=0.011)。
- 电子鼻将恶性结节患者转至无活检治疗的人数多于Swensen和Brock模型(高风险组:27 vs 19和6,p=0.057和p<0.001)。
关键数值与推荐
- 风险分层:低风险<0.2;中风险≥0.2-0.7;高风险≥0.7。
- 主要结局为电子鼻与组织病理相比的诊断性能(准确率和F1评分);次要结局为电子鼻与临床影像预测模型相比的临床性能。
临床怎么用
- 作者认为,在临床Ⅰ期肺癌中电子鼻技术可作为影像学的补充或作为「多组学」平台的一部分使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Electronic nose (E-nose) technology has reported excellent sensitivity and specificity in the setting of lung cancer screening. However, the performance of E-nose specifically for early-stage tumors remains unclear. Therefore, the aim of our study was to assess the diagnostic performance of E-nose technology in clinical stage I lung cancer. METHODS: This phase IIc trial (NCT04734145) included patients diagnosed with a single greater than or equal to 50% solid stage I nodule. Exhalates were prospectively collected from January 2020 to August 2023. Blinded bioengineers analyzed the exhalates, using E-nose technology to determine the probability of malignancy. Patients were stratified into three risk groups (low-risk, [<0.2]; moderate-risk, [≥0.2-0.7]; high-risk, [≥0.7]). The primary outcome was the diagnostic performance of E-nose versus histopathology (accuracy and F1 score). The secondary outcome was the clinical performance of the E-nose versus clinicoradiological prediction models. RESULTS: Based on the predefined cutoff (<0.20), E-nose agreed with histopathologic results in 86% of cases, achieving an F1 score of 92.5%, based on 86 true positives, two false negatives, and 12 false positives (n = 100). E-nose would refer fewer patients with malignant nodules to observation (low-risk: 2 versus 9 and 11, respectively; p = 0.028 and p = 0.011) than would the Swensen and Brock models and more patients with malignant nodules to treatment without biopsy (high-risk: 27 versus 19 and 6, respectively; p = 0.057 and p < 0.001). CONCLUSIONS: In the setting of clinical stage I lung cancer, E-nose agrees well with histopathology. Accordingly, E-nose technology can be used in addition to imaging or as part of a "multiomics" platform.
引用
- Rocco G, Pennazza G, Tan KS, et al. A Real-World Assessment of Stage I Lung Cancer Through Electronic Nose Technology. J Thorac Oncol. 2024. PMID: 38762120. doi:10.1016/j.jtho.2024.05.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。